The CME CF Bitcoin Reference Rate - New York Variant (BRRNY) is a once a day benchmark index price for Bitcoin that aggregates trade data from multiple Bitcoin-USD markets operated by major cryptocurrency exchanges that conform to the CME CF Constituent Exchange Criteria. It is the pre-eminent index price for Bitcoin risk settlement that is synchronized to the traditional US financial market close of 1600 New York Time. The Index is a Registered Benchmark under UK BMR and as such is a Third Country benchmark under the EU BMR Regime.
Watch our video here
For additional information, please visit:
https://www.cfbenchmarks.com/data/indices/BRRNY
The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell any of the underlying instruments cited including but not limited to cryptoassets, financial instruments or any instruments that reference any index provided by CF Benchmarks Ltd. This communication is not intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. Please contact your financial adviser or professional before making an investment decision.
Note: Some of the underlying instruments cited within this material may be restricted to certain customer categories in certain jurisdictions.
We explore the rise of Kraken's xStocks with Mark Greenberg, Head of B2B at Payward Services / Kraken, and Thomas Erdösi, Head of Product at CF Benchmarks.

Ken Odeluga
Momentum Leads as the Market Sells Off The market declined 3.1% on the week, giving back a portion of the rally that had narrowed the year-to-date drawdown over recent weeks. The year-to-date loss now stands at 30.6%. The best performer this week is momentum, which topped the weekly factor rankings for the first time this year at +1.5%, a meaningful gap over the others. Value held up relatively well at -0.1% on the week, while growth posted a modest decline of 0.5%. Downside beta fell 2.1% on

Mark Pilipczuk
We're pleased to share a short video overview of the Q1 2026 Reconstitution of our CF Capitalization Series — a suite of indices regulated under the UK Benchmark Regulation (BMR) — presented by our Head of Product, Thomas Erdösi.

CF Benchmarks